Perhaps 50 years from now, the organ needed for thousands of patients awaiting an organ transplant each year will be printed on 3D bioprinters. The limbs that need to be transplanted to 1 million patients waiting for organs in the world will be produced by a machine. It is an imaginary scenario but actually very close to the real thing …
Currently, organs that can be used in humans cannot be made. However, the first step in this is local technologies that print bone and corneal implants. In Turkey in May 2017 Onur Samet Yildirim Y Can Garipoglu produce three-dimensional bioprinting systems established by Axolotl biosystems he is among those who do this.
Used in almost 50 universities
The company produces leather textures with materials found in human nature. Plus, it combines the right mixes of materials like collagen, calcium, magnesium, and phosphate with cells. Corneal implants can produce soluble materials for surgery. The CEO of the company, Onur Samet Yıldırım, says that they have focused mainly on automatic control systems and biomedical systems and continues his words as follows: “Before Axolotl Biosystems, we established a rapid prototyping company of electronic circuits. with the support of the Ministry of Industry. knowledge and business experience. Later, with the use of the technology that we develop in biomedical projects, we adapt to this field ”.
One of DCP’s investments
Axolotl develops biosystems, tissue engineering and regenerative medicine devices. In this sense, the star product group is 3D bioprinting systems … The company continues to grow with this. Yıldırım said: “Bioprinting systems are systems that allow you to create artificial tissues and organoids. We have created our go-to-market strategy on these products. We can summarize the development process of bioprinting systems as follows. He says that went through the stages.
The company, ITU ARI Techno, Diffusion Capital Partners and Turkey Technology Development Foundation received from the 150 thousand dollars they started working with the investment. Yıldırım, who stated that they established the company on an export basis, said: “We have installed 3D bioprinting systems in almost 50 universities in the US and Europe. Our main goal by 2021 is to reach almost 100 universities in the west. and the center Markets of Europe, Far East and North America “, reveals the objective of growth.
Destinations, markets in the Far East and Western Europe
We currently have a distribution network that allows us to operate in many points abroad. Distributors in countries such as Germany, Belenux (based in Holland), UK, France, Scandinavia (based in Denmark) China, India and Singapore … Onur Samet Yıldırım, “In this regard, strengthen our position in the Far East and the short-term Western European markets are the basic structure of our growth abroad. ”Bioprinting technologies have become an FDA approved therapeutic treatment method starting this year. In this sense, we believe that it will be used more actively in clinical studies. “
Since March, the company has been developing an isothermal DNA amplification test device that can result in compatible RT-PCR devices used for coronavirus testing. It will be possible to get a coronavirus test result in 30 minutes with this device.
Yıldırım explains his objectives in the project as follows: “It was to allow multiple tests on a single platform by manipulating the Bioprinting system as an automatic pipetting system. Thus, the user effect would be eliminated and it would be possible to increase the precision. In this context We have been doing our work since March. We received support from Petrol Ofisi for the project. “